Eli Lilly announced a $3.5 billion investment to build a new pharmaceutical manufacturing facility in Fogelsville, Lehigh Valley, Pennsylvania. The plant will be the company’s fourth U.S. site and will add significant injectable drug capacity to support its rapidly growing obesity and diabetes portfolio.
The new facility is slated to create 850 full‑time jobs and an additional 2,000 construction positions. Construction is expected to begin in 2026, with the plant becoming operational in 2031. Eli Lilly will incorporate advanced artificial‑intelligence and machine‑learning systems to optimize production and ensure a reliable supply of medicines.
The plant’s primary focus will be the production of next‑generation weight‑loss medicines, including the investigational triple‑agonist retatrutide, and to expand capacity for its flagship injectable drugs. The expansion is designed to meet the surging demand for Mounjaro and Zepbound, which together generated more than $10 billion in sales in the first three quarters of 2025.
Eli Lilly’s investment reflects a broader strategy to strengthen domestic manufacturing, reduce supply‑chain risk, and maintain a competitive edge in the high‑growth obesity market. The Pennsylvania site follows similar announcements in Texas, Virginia, and Alabama, underscoring the company’s commitment to reshoring production and supporting its pipeline of next‑generation therapies.
CEO David A. Ricks said, “Our mission starts with patients and delivering the medicines they need. To meet increasing demand, we’re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight‑loss medicines. We’re creating high‑quality jobs and collaborating across the region—suppliers, educators, and workforce‑development partners—to make critical medicines in the U.S. That’s our commitment—to patients, to our new Pennsylvania home, and to our country.”
The announcement follows Eli Lilly’s record Q3 2025 earnings, where sales of its GLP‑1 drugs surged more than 50% year‑over‑year. The new plant signals confidence in the long‑term growth of the obesity and diabetes markets and reinforces the company’s strategy to secure supply chains and sustain its leadership position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.